Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07927088
NA

Halova Vaginal Ovules Versus Placebo for Genitourinary Symptoms in Premenopausal Women

Sponsor: Perfect Care Distribution

View on ClinicalTrials.gov

Summary

This post-market clinical study evaluated whether Halova vaginal ovules improve vaginal dryness and other genitourinary symptoms in premenopausal women and assessed their safety. The main questions were: * Does Halova reduce the severity of vaginal dryness and other bothersome genitourinary symptoms compared with placebo? * Does Halova improve vaginal health, vaginal pH, and sexual function? * What adverse events occur during treatment with Halova? * Are the treatment effects maintained after treatment is discontinued? Researchers compared Halova with placebo in a randomized, double-blind, 2:1 design. Participants: * Used Halova vaginal ovules or placebo once daily for 10 consecutive days per month, during the intermenstrual period, for 3 months * Attended study assessments at baseline, week 12, and week 24 * Were evaluated for symptoms, vaginal health, vaginal pH, sexual function, safety, and persistence of treatment effects * Completed a questionnaire on knowledge and attitudes regarding premenopause and menopause at baseline and at week 12

Official title: A Post-Authorization, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Halova Vaginal Ovules in the Management of Symptoms of Genitourinary Syndrome in Premenopausal Women.

Key Details

Gender

FEMALE

Age Range

40 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2025-02-22

Completion Date

2026-06-17

Last Updated

2026-11-09

Healthy Volunteers

No

Interventions

DEVICE

Halova vaginal ovules

Halova is a vaginal medical device formulated as ovules containing sodium hyaluronate (5 mg per ovule) and xylitol (3 mg per ovule), together with semi-synthetic glycerides, lanolin, Aloe vera oil extract, Calendula officinalis extract, colloidal silicon dioxide, and vitamin E. One ovule was administered intravaginally once daily, preferably in the evening, for 10 consecutive days per month, during the intermenstrual period, for three consecutive months.

DEVICE

Placebo vaginal ovules

Placebo vaginal ovules consisted of the same lipid-based excipient matrix as the investigational product, without sodium hyaluronate and xylitol. The placebo was designed to maintain blinding and was administered according to the same schedule as the active intervention.

Locations (1)

Arad County Clinical Emergency Hospital - Department of Obstetrics and Gynecology

Arad, Romania